Alexandre Benjo, MD
Interventional Cardiology · Tucson, AZNPI 1164606448
Payments from drug & device makers
Across 424 payments — averaging $36.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$4K
- Medtronic$3K
- Cvrx, Inc.$2K
- Johnson & Johnson$1K
- Novartis$972
- Impulse Dynamics (USA) Inc.$624
- plus $4K from 32 others
What the payments were for
- Travel & lodging$1,3449%
- Food & beverage$14,03191%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 80 | $3,578 |
| Medtronic(2 entities) | 51 | $2,964 |
| Cvrx, Inc. | 25 | $1,840 |
| Johnson & Johnson | 62 | $1,204 |
| Novartis | 51 | $972 |
| Impulse Dynamics (USA) Inc. | 13 | $624 |
| E.r. Squibb & Sons, L.L.C. | 24 | $411 |
| Kestra Medical Technology Services, Inc. | 18 | $397 |
| Abiomed | 6 | $395 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 13 | $369 |
| Merck | 12 | $345 |
| Biotronik Inc. | 5 | $317 |
| Edwards Lifesciences | 2 | $316 |
| Actelion Pharmaceuticals US, Inc. | 6 | $174 |
| Biosense Webster, Inc. | 2 | $149 |
| Elutia, Inc. | 1 | $137 |
| Cardiva Medical, Inc. | 4 | $125 |
| Angiodynamics, Inc. | 1 | $112 |
| Pfizer | 2 | $111 |
| AstraZeneca | 5 | $88 |
| Boston Scientific | 5 | $81 |
| Bard Peripheral Vascular, Inc. | 2 | $81 |
| Amarin Pharma, Inc. | 4 | $70 |
| Inari Medical, Inc. | 3 | $68 |
| Lundbeck LLC | 3 | $66 |
| Amgen | 4 | $61 |
| Boehringer Ingelheim | 3 | $52 |
| Cardiovascular Systems Inc. | 5 | $52 |
| Novo Nordisk | 2 | $39 |
| Chiesi USA, Inc. | 2 | $37 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $24 |
| Atricure, Inc. | 1 | $24 |
| Vital Connect, Inc | 1 | $22 |
| Bayer | 1 | $19 |
| Itamar Medical Inc | 1 | $18 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $18 |
| Bardy Diagnostics, Inc. | 1 | $15 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$1,178
- ClosureFast$845
- CARDIOMEMS$798
- Micra$666
- OPTIMIZER$523
- XARELTO$237
- SAPIEN 3 Ultra RESILIA$160
- EMBOSHIELD NAV6$153
- ECM Patch,Pouch$137
- CAMZYOS$123
- WINREVAIR$123
- LifeVest$119
- LEQVIO$118
- Evera$113
- Auryon Laser System 100-120 Vac$112
- Carto 3$105
- Quadra Allure MP RF CRT Pacemkr$105
- Reveal LINQ$105
- VenaSeal$103
- Fortify Assura, Ellipse ICD$100
How this compares
$15,388 in reported general payments places this provider in the 55th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 87 | $118,654 |
| XareltoRivaroxaban | 85 | $94,149 |
| EntrestoSacubitril/Valsartan | 20 | $23,094 |
| Bisoprolol Fumarate | 337 | $9,393 |
| Labetalol Hcl | 69 | $3,487 |
| Ranolazine ErRanolazine | 51 | $3,174 |
| Rosuvastatin Calcium | 162 | $2,041 |
| ClopidogrelClopidogrel Bisulfate | 135 | $1,826 |
| Atorvastatin Calcium | 96 | $1,350 |
| Metoprolol Succinate | 89 | $1,025 |
| Amlodipine Besylate | 174 | $917 |
| Amiodarone Hcl | 19 | $857 |
| Ezetimibe | 30 | $808 |
| Cilostazol | 32 | $774 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 55 | $519 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $111 | $118,65487 claims |
| Johnson & JohnsonXarelto | $1,204 | $94,14985 claims |
| NovartisEntresto | $972 | $23,09420 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Tucson
- Thomas WaggonerTucson$4.1M
- Ajay TuliTucson$705K
- Kapildeo LotunTucson$488K
- Neil GheewalaTucson$319K
- Ryan TsudaTucson$245K
- Michel CorbanTucson$106K
- Dexter de LeonTucson$90K
- William ThomasTucson$71K
- Brenda PeartTucson$66K
- Ranjith ShettyTucson$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.